DIO Corporation (KOSDAQ:039840)
17,210
+100 (0.58%)
At close: Dec 5, 2025
DIO Corporation Revenue
DIO Corporation had revenue of 41.45B KRW in the quarter ending September 30, 2025, with 32.23% growth. This brings the company's revenue in the last twelve months to 155.15B, up 37.84% year-over-year. In the year 2024, DIO Corporation had annual revenue of 119.65B, down -23.21%.
Revenue (ttm)
155.15B
Revenue Growth
+37.84%
P/S Ratio
1.49
Revenue / Employee
323.91M
Employees
1,749
Market Cap
230.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.65B | -36.17B | -23.21% |
| Dec 31, 2023 | 155.82B | 24.51B | 18.67% |
| Dec 31, 2022 | 131.31B | -18.73B | -12.48% |
| Dec 31, 2021 | 150.04B | 29.98B | 24.97% |
| Dec 31, 2020 | 120.06B | -7.11B | -5.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |